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ABSTRACT
Leigh syndrome (LS) is a mitochondrial progressive encephalopathy characterized by bilateral symmet-
ric necrotic lesions of the central nervous system. Maternally inherited Leigh Syndrome (MILS) repre-
sents 10–20% of LS. Mutations in MT-ATP6 are the most common, being m.8993T>C/G the classical
mutations. Molecular diagnosis for mitochondrial diseases is always a challenge and Multiplex ligation-
dependent probe amplification (MLPA) of mitochondrial DNA can be an initial test for molecular diag-
nosis, although it is not widely used. We present a MILS patient in which MLPA was able to detect the
common m.8993 T>G mutation and serve as a first approach for the definite molecular diagnosis.
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Mitochondrial disorders are a heterogeneous group of dis-
eases caused by genetically determined mitochondrial dys-
function. The mitochondrial proteome (1500 proteins)
(Meisinger et al. 2008) has a dual genetic origin (mitochon-
drial and nuclear DNA). Mitochondrial DNA (mtDNA) is a
16.5kb circular DNA inherited exclusively from maternal
mitochondria that encodes for 13 proteins along with 22
tRNAs and 2 rRNAs necessary for their transcription and
translation. A cell can have 100 to1000 mitochondria, each of
which can bear 2–10 mtDNA copies, and copies can differ
from each other, feature that is known as ‘heteroplasmy’. The
rest of the mitochondrial proteins are encoded by nuclear
DNA and travel to the mitochondria after being traduced in
the cytoplasm. Thus, mitochondrial diseases can be inherited
through a maternal mtDNA or a Mendelian pattern.
Leigh syndrome (LS) is a mitochondrial progressive
encephalopathy characterized by bilateral symmetric necrotic
lesions of the central nervous system involving the brainstem
and/or basal ganglia structures. Usually, disease onset is early
in the first year of life, progression is quick and ends with
the child’s life before the age of 3 (Rahman et al. 1996). In
cases of late onset, disease progression can be slower
(Wesolowska et al. 2015). A broad variety of genetic altera-
tions can cause this disease, including nuclear and mtDNA
mutations. More than 75 different genes have been associ-
ated with LS (Lake et al. 2016) and most of these genes
encode for mitochondrial complex proteins or proteins
crucial for their correct functioning.
Maternally inherited Leigh Syndrome (MILS) represents
10–20% of LS. Mutations in complex 1 (MT-ND1) and com-
plex V (MT-ATP6) are the most common causes, being MT-
ATP6 the most important (10%). The classical devastating
MILS is caused by high heteroplasmic (>90%) mutations in
the MT-ATP6 gene, being position m.8993 the mutation hot
spot for m.8993T>G or T>C. When heteroplasmy is lower
(70%) these mutations can cause a later onset form of the
disease called NARP syndrome (neuropathyþ ataxiaþ retinitis
pigmentosa) (B€ulent et al. 2012).
Molecular diagnosis for mitochondrial diseases is always a
challenge. Guidelines suggest looking first in mtDNA for com-
mon mutations and deletions (Chi 2015; Parikh et al. 2015).
Next-generation sequencing has become the first line
approach in many parts of the world. However, in developing
countries this is not available as a first step option. Multiplex
ligation-dependent probe amplification (MLPA) (Schouten
et al. 2002) can be used as an initial study for molecular char-
acterization of mitochondrial diseases since it has been
shown to be sensible enough to detect mutations.
Materials and methods
Patient consent and clinical information
Informed consent was obtained from the patient’s mother in
order to publish this case report. Clinical data were gathered
from the patient’s clinical records.
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DNA isolation
Blood was withdrawn from the patient and her mother and
frozen at 20 C for 24–48h, after which it was thawed. Total
DNA was extracted with a Cetyl Trimethylammonium
Bromide (CTAB)/chloroform-isoamylic based protocol.
Leukocytes were isolated with 3–4 T10E10 washes and then
suspended in CTAB solution (2 g/l CTAB Sigma AldrichVR ,
St Louis, MO, 100mM Tris/HCl, 20mM EDTA, 1.4M NaCl, and
2% 2-mercaptoethanol) and incubated at 60 C for 1 hour.
Then chloroform-isoamyl alcohol solution (24:1) was added
and the samples were centrifuged. The aqueous phase was
collected into a new tube and mixed with three volumes of
ice-cold 100% ethanol. Precipitated DNA was dissolved in
T10E0.1 buffer and stored at 20 C for further use.
mtDNA MLPA
This technique was performed on the patient and her
mother’s leukocyte DNA using the P125-B1 SALSA MLPA kit
Figure 1. Patient and mother’s molecular characterization. Left column: patient’s studies; right column: mother’s studies. The large arrows shows the genetic diag-
nostic work-flow that was used in this case. (A and C) Patient and mother’s mtDNA MLPA Ratio chart analyzed by Gene Marker v. 1.75. Boxes in between the hori-
zontal lines correspond to ratios for regions which are present in a normal copy number. Boxes below or above the horizontal lines correspond to ratios for regions
which are deleted or duplicated in the analyzed sample. Black triangles: represent ratios for sequence mutated regions (m.3243A>G, m.3460G>A, m.8344A>G,
m.11778G>A, and m.14484T> C). Small arrows point to the m.8957–m.9023 probe, found with no amplification signal in the patient and with normal amplifica-
tion signal in the mother. Amplification signal of probes for two mutation-specific regions is observable. These probes (14484T> C and 8344A>G) can give a low
signal in wild-type mtDNA and should have a 10-fold augmentation to consider the presence of a mutation, which is not seen in these cases. In the patient’s assay,
the smallest amplified region (first left ratio) seems to be duplicated, this fragment corresponds to a sequence located in the D-loop, where the origin of replication
of the heavy mtDNA strand begins, making it a three-strand structure, which can explain this finding. (B and D) Patient and mother’s MT-ATP6 Sanger sequencing:
the small arrows point to the m.8993T>G mutation found in homoplasmy in the patient and heteroplasmy in the mother.
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(MRC-HollandVR , Netherlands). One nanogram of total DNA
was used as a template, previously treated with 1 ml of
0.5mg/ml RNase (BiodynamicsVR , Argentina). After probe
hybridization and ligation, PCR was carried out and the amp-
lification products were run on an ABI3130 DNA analyzer
(Applied BiosystemsVR ), Foster City, CA)VR As control samples,
DNA from a pool of leukocytes from 10 healthy individuals
was used. Peak plots of patient, mother, and control samples
were visualized and normalized using GeneMarker software v.
1.75 (SoftGeneticsVR , State College, PA) to establish a dosage
ratio of mutated mtDNAs.
An altered ratio was considered according to standard cut
off values for MLPA analyses (1.3 and 0.7).
Sanger sequencing
A fragment of the MT-ATP6 gene was amplified using the fol-
lowing primer set (50-30): Forward AATGCCCTAGCCCACTTCTT
(m.8893–8912) and Reverse TCATTAGGAGGGCTGAGAGG
(9272–9288). Direct sequencing of the PCR products was




Baby girl from a non-consanguineous healthy couple who
was presented at 3 months of age with central hypotonia,
milestone regression, encephalopathy, hyperlactacidemia, and
seizures. She also had a hypertrophic cardiomyopathy that
required treatment with beta blockers. Her brain MRI showed
symmetric necrotic lesions in the basal ganglia and brainstem
and the spectroscopy revealed an important lactic acid peak.
Her biochemical metabolic work-up showed increased lactic,
pyruvic, succinic, and fumaric acids in the urine. Plasma
amino acids revealed high Alanine with normal Citrulline.
Blood acylcarnitines were unremarkable. Family history
revealed a maternal half-brother that had had similar clinical
findings and died at 7 months of age with no diagnosis. The
patient’s clinical record plus the family history made MILS the
most probable diagnosis.
Patient and mother’s genetic findings
As a first step in the approach to molecular diagnosis,
mtDNA MLPA was performed on the patient’s leukocyte
DNA. The probe that hybridizes with mtDNA between posi-
tions m.8957 and m.9023 did not amplify at all in the
patient’s sample (Figure 1(A)). This made us speculate that
there was a mutation in that region that was blocking the
probe’s hybridization, ligation, and amplification. The next
step was to sequence that region. Sanger sequencing of the
patient’s MT-ATP6 gene revealed the mutation m.8993T>G
in homoplasmy (Figure 1(B)). The mother’s DNA showed the
same mutation in heteroplasmy (Figure 1(C)).
To see if we could determine the mother’s heteroplasmy
level more accurately, we performed mtDNA MLPA on the
mother’s DNA. The m.8957–m.9023 probe amplified in the
same range as the controls’, concluding that the m.8993T>G
mutation’s heteroplasmy level was undetectable with this
technique (Figure 1(D)). Since mtDNA MLPA has been shown
to detect a 20% heteroplasmy level (Mayorga et al. 2016), we
assume that the mother’s heteroplasmy was below this value.
Discussion
MtDNA is still analyzed at a first approach for genetic diagno-
sis of mitochondrial diseases (Chi 2015). Even though the
world is tending to use next-generation sequencing techni-
ques from the onset, in developing countries this is still not
possible due to the high cost and low availability. MLPA can
be a good option to explore initially mtDNA (Kwon et al.
2011; Tonska et al. 2012), and here we see that it is sensible
enough to detect a single base change. Even though the
mtDNA MLPA commercial kit was not designed to detect the
mutant m.8993 T>G/C DNA, it does detect the wild-type
DNA of that region. Thus, low or lack of amplification of that
MT-ATP6 probe should raise suspicion of a mutation in
the region.
In conclusion, we propose mtDNA MLPA as a first line
diagnostic tool for mitochondrial diseases as it is affordable,
easy, and can detect mtDNA deletions and mutations in a
single assay.
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